NTM drug discovery: status, gaps and the way forward

Mu Lu Wu, Dinah B. Aziz, Véronique Dartois, Thomas Dick

Research output: Contribution to journalReview articlepeer-review

156 Scopus citations


Incidence of pulmonary diseases caused by non-tuberculous mycobacteria (NTM), relatives of Mycobacterium tuberculosis, is increasing at an alarming rate, surpassing tuberculosis in many countries. Current chemotherapies require long treatment times and the clinical outcomes are often disappointing. There is an urgent medical need to discover and develop new, more-efficacious anti-NTM drugs. In this review, we summarize the current status of NTM drug development, and highlight knowledge gaps and scientific obstacles in NTM drug discovery. We propose strategies to reduce biological uncertainties and to begin to populate a NTM drug pipeline with attractive leads and drug candidates. From crisis to cures – a review on status, knowledge gaps and major obstacles in NTM drug discovery and development, and how to move forward.

Original languageEnglish (US)
Pages (from-to)1502-1519
Number of pages18
JournalDrug Discovery Today
Issue number8
StatePublished - Aug 2018

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'NTM drug discovery: status, gaps and the way forward'. Together they form a unique fingerprint.

Cite this